Abbott D2E7 Patient Rollover From Access Program Will Follow Kaletra Model
Executive Summary
Abbott will use its experience from the Kaletra launch to convert rheumatoid arthritis patients out of D2E7's patient access program and onto paid drug following the expected 2003 approval of the tumor necrosis factor inhibitor
You may also be interested in...
Abbott’s D2E7 is Humira
Abbott selects Humira as trade name for tumor necrosis factor inhibitor D2E7/adalimumab. Abbott submitted a BLA for rheumatoid arthritis April 2 and expects to launch in the first half of 2003. Humira will be the first product manufactured at Abbott's biotech plant in Barceloneta, Puerto Rico upon completion of the $350 mil. facility. Abbott also recently expanded its bioresearch center in Worcester, Mass. (1"The Pink Sheet" Oct. 14, p. 27)...
Abbott’s D2E7 is Humira
Abbott selects Humira as trade name for tumor necrosis factor inhibitor D2E7/adalimumab. Abbott submitted a BLA for rheumatoid arthritis April 2 and expects to launch in the first half of 2003. Humira will be the first product manufactured at Abbott's biotech plant in Barceloneta, Puerto Rico upon completion of the $350 mil. facility. Abbott also recently expanded its bioresearch center in Worcester, Mass. (1"The Pink Sheet" Oct. 14, p. 27)...
Senate Medicare Rx Plans: Oral Chemo, Self-Injectables May Be Fallback
Legislation extending Medicare coverage to oral chemotherapy drugs and self-injectables is among the fallback steps under consideration in the Senate Finance Committee if Congress fails to pass a comprehensive drug benefit this year